• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 13, 2021

View Archived Issues
Syringe with Johnson and Johnson logo

Rare clotting cases prompt FDA, CDC to pause rollout of J&J COVID-19 vaccine

The FDA and the CDC have jointly recommended a temporary pause in the further rollout of Johnson & Johnson Co.’s COVID-19 vaccine while they investigate six rare clotting cases in adults ages 18 to 48. Read More
europe-uk-flag-map.png

Moderna, Novavax COVID-19 vaccines added to U.K. mixed dosing regimen study

LONDON – The U.K. is moving on to the next phase of testing mixed dosing schedules for COVID-19 vaccines, launching a study in which it will assess the effect of using Moderna Inc. or Novavax Inc.’s products as the second dose in a heterologous prime boost trial. Read More
Handshake with DNA, molecules

Senti enters a $645M deal with Spark

Senti Biosciences Inc. stands to receive more than $645 million in up-front, opt-in and milestone payments through a new collaboration and option agreement with Spark Therapeutics Inc. Read More

Theseus Pharmaceuticals raises $100M series B for pan-variant kinase inhibitors

Theseus Pharmaceuticals Inc., a startup developing new tyrosine kinase inhibitors to overcome treatment-resistant cancer mutations, has raised $100 million in a series B financing led by Foresite Capital. Co-founded at the health care investment firm Orbimed with former Ariad Pharmaceuticals Inc. scientists who pioneered the development of pan-variant kinase inhibitors, the company's lead candidate is THE-630, a next-generation pan-variant KIT inhibitor for the potential treatment of refractory gastrointestinal stromal tumors. Read More
FDA icons

Adcom to explore first islet cell therapy for diabetes relief

The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee will be venturing into new territory April 15 in which it not only has to consider whether the benefit of Celltrans Inc.’s donislecel is clinically meaningful, but it also will have to define the indication. Read More

Aspirin to greatness in cardio, Plx readies liquid Vazalore launch

Plx Pharma Inc. is not letting out the details just yet about next quarter’s launch of liquid-filled aspirin capsule Vazalore, recently cleared by the FDA in 81-mg and 325-mg doses, but CEO Natasha Giordano said cardiologists are “essential to our strategy. We have developed very deep sales plans [that are] laser-focused.” Read More

China launches policies to encourage innovation, but pricing and payment remain pain points

SHANGHAI – China’s regulatory environment has evolved to encourage drug innovation, but despite remarkable progress, mounting pricing pressure from the government and a weak insurance sector remain as barriers. Read More

Regulators need to up their game to support drugmakers’ global drug development, experts urge

Speaking during the 2021 China Pharmaceutical Innovation 100 Summit, industry insiders called for more regulatory talent and even an organizational revamp to clear innovative products faster and support the global development strategies of Chinese drugmakers. Read More
Map of Australia as blue circuit board, digital network

Australia lays out medical product manufacturing priorities to shore up future supply chains post-pandemic

PERTH, Australia – In the aftermath of the COVID-19 pandemic, Australia is shoring up its national supply of medical products and making it a national priority to drive economic recovery and ensure future resilience. The objective of the government’s modern manufacturing strategy is to build scale and capture income in high-value areas of manufacturing where Australia either has established competitive strength or emerging priorities. Read More

Appointments and advancements for April 13, 2021

New hires and promotions in the biopharma industry, including: Aavantibio, Adicet, Albireo, Amarin, Amarin, Atriva, Candel, Eli Lilly, Kane, Landos, Lixte, Oncternal, Orion, Rain, Yumanity. Read More

Conference data for April 13, 2021: AACR

New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research Annual Meeting 2021, including: BMS, Kronos, Kymera, Medicenna, Medigene, Mei, Mersana, Mirati, Molecular Partners, Molecular Templates, Morphic, Nextcure, Nuvalent, Oasmia, Oncolytics, Oncomyx, Oncurious, Oncternal, Oric, Pharmabcine, Phio, Pieris, PMV, Puretech, Schrodinger, Seneca. Read More

Financings for April 13, 2021

Biopharmas raising money in public or private financings, including: Arcellx, Briacell, Cerevel, Crinetics, GH, Jaguar, Onxeo, Recursion, Repertoire, Xoma. Read More

In the clinic for April 13, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Adagio, Akari, Apellis, Atriva, Bausch + Lomb, Boehringer, Cardiol, Epiendo, Geron, Iterion, Kinarus, Lindis, Longeveron, Mei, Merck, Nasus, Otsuka, Peptilogics, Prexa Sante, Rigel, Synlogic, Vallon, Valneva. Read More

Other news to note for April 13, 2021

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: 9 Meters, Actimed, AGTC, Akers, Aytu, Biomica, BMS, Bridgebio, Cybin, Denovo, Evogene, Evotec, Eyam, Faraday, Intravacc, Kiadis, Merck KGaA, Mymd, Nkgen, Philogen, Rumpus, Sanofi, Teamedon, Therapeutic Solutions. Read More

Regulatory actions for April 13, 2021

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Akouos, Avenue, Axcella Health, Celularity, Janssen, Kibow, Lintonpharm, Neuraptive, Novartis, RDIF, Vtv. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe